{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/nausea-vomiting-in-pregnancy/prescribing-information/promethazine/","result":{"pageContext":{"chapter":{"id":"715f035d-267f-5933-b2b0-7d3ee3bd6430","slug":"promethazine","fullItemName":"Promethazine","depth":2,"htmlHeader":"<!-- begin field 8778f769-4baa-43cf-8090-a77400a6aff0 --><h2>Promethazine</h2><!-- end field 8778f769-4baa-43cf-8090-a77400a6aff0 -->","summary":"","htmlStringContent":"<!-- begin item 331cf2eb-28d5-4082-9ae1-a77400a6adb1 --><!-- end item 331cf2eb-28d5-4082-9ae1-a77400a6adb1 -->","topic":{"id":"5d1ac05e-2e14-5b50-9a55-84ebd62fb88a","topicId":"866e168a-d1cc-4f14-ae38-2264dad4909d","topicName":"Nausea/vomiting in pregnancy","slug":"nausea-vomiting-in-pregnancy","lastRevised":"Last revised in November 2020","chapters":[{"id":"2ed30ea1-6303-508e-bc93-066f8ffbbba6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"81163ec6-a53e-53b1-9990-910cceb0be62","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9f99e883-ffa1-5d97-b703-d5bfbd68f8d5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"81c02d2d-db72-591c-9cac-e581388698c4","slug":"changes","fullItemName":"Changes"},{"id":"845aae6a-8e35-57f1-b583-4763434044df","slug":"update","fullItemName":"Update"}]},{"id":"21afb631-a6c0-5829-b00a-3b33bef92b50","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"61081bb4-4afa-59ad-8401-21a133c7ac1e","slug":"goals","fullItemName":"Goals"},{"id":"5e20514d-0378-56ab-a9c4-6adb3b054200","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5af11c90-393d-59dd-9a48-c750bc1a8a14","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"51bcef1b-8089-52c9-92cc-1fa55932d88b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ef8fc985-dc5b-58a5-a2ff-ca6e9d55cfb8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f559ccd0-5b31-5044-9e75-d75ab6224e12","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2664bbce-4231-58ba-94b3-9154bbe463ce","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"474f1c82-889d-5487-9620-c2c4c6869f1b","slug":"definition","fullItemName":"Definition"},{"id":"8eb8a14e-f0bc-5bde-941f-077c2ebf80e8","slug":"causes","fullItemName":"Causes"},{"id":"6086e58d-ce8f-56ba-8bc9-6769de656e20","slug":"associated-factors","fullItemName":"Associated factors"},{"id":"843ada21-2019-53fe-96b9-02ac02e7d0f2","slug":"prevalence","fullItemName":"Prevalence"},{"id":"87b6f2c0-0cd6-59f3-9359-e145dc966385","slug":"complications","fullItemName":"Complications"}]},{"id":"d56e419a-1cce-586b-b99b-a5b8a8990006","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1f17249a-f4a8-55a7-aac0-221f3958f18f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b917da16-f352-5806-8109-438dbc9bbf0b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"92cdc482-cd10-5234-96f9-a47cf0d7a2d1","fullItemName":"Management","slug":"management","subChapters":[{"id":"110c4bdc-fe27-5536-9a99-bfbcf04edc46","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"93dd4a9b-e268-51a6-ad4d-89d5e9f8a3ab","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f416e06b-d171-5ff0-8c08-5bc1edd42843","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"130049ea-689b-545a-a2c3-05f0dd6e75a9","slug":"metoclopramide","fullItemName":"Metoclopramide"},{"id":"b1e3f566-e2f8-55a2-989a-e0a05d5ec1e2","slug":"ondansetron","fullItemName":"Ondansetron"},{"id":"5ab79693-69e2-58b9-b27b-5ccf74d1a7b5","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"715f035d-267f-5933-b2b0-7d3ee3bd6430","slug":"promethazine","fullItemName":"Promethazine"}]},{"id":"85b35812-d5b1-58c1-83b2-54c180386588","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1a1884de-e81c-54af-b11f-6b0868c50cc8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8a6cb0f6-92e2-57f4-9a1e-bf9e54371e08","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4dc13c44-10ce-581a-a0a4-039b81c0c21e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cb1eb43f-2d9f-59be-8318-3bd84b8d0c3f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4b024ff4-e12a-55bd-ae23-668d6ca9e645","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e5cef950-067b-517f-9adb-2be42bf3be6f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"dbe95893-89e8-5737-9b03-95b5280f9823","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"93dd4a9b-e268-51a6-ad4d-89d5e9f8a3ab","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"7afb6912-8f3c-5b58-bdb5-336309fc1459","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 334ad44b-4aa0-4c7c-a680-a77400a9b22e --><h3>What dosage of promethazine should I prescribe?</h3><!-- end field 334ad44b-4aa0-4c7c-a680-a77400a9b22e -->","summary":"","htmlStringContent":"<!-- begin item b0311148-6762-4514-bfc9-a77400a9b024 --><!-- begin field cd1fd2d8-c502-49fd-967d-a77400a9b22e --><ul><li><strong>Promethazine </strong>is available as promethazine hydrochloride or promethazine teoclate. Either preparation may be used: <ul><li><strong>Promethazine hydrochloride </strong>is available in two strengths — 10 mg or 25 mg tablets. Prescribe up to 25 mg as one dose at bedtime, and repeat in the morning if necessary.</li><li><strong>Promethazine teoclate </strong>is available as 25 mg tablets. Prescribe 25 mg at bedtime. The dose may be increased to 100 mg daily. </li></ul></li></ul><!-- end field cd1fd2d8-c502-49fd-967d-a77400a9b22e --><!-- end item b0311148-6762-4514-bfc9-a77400a9b024 -->","subChapters":[]},{"id":"501766d2-974b-5483-99c0-e9bf14fbcb9d","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field cd81a225-3c83-4683-9188-a77400a9da1e --><h3>What are the adverse effects of promethazine?</h3><!-- end field cd81a225-3c83-4683-9188-a77400a9da1e -->","summary":"","htmlStringContent":"<!-- begin item db4ee633-6ae3-4d89-9fbe-a77400a9d771 --><!-- begin field b8b47938-9096-4cea-ba7d-a77400a9da1e --><p><strong>Adverse effects of promethazine include:</strong></p><ul><li>Neurological — dizziness, confusion, headaches, nightmares, sedation which can persist for up to 12 hours (affected people should not drive or operate heavy machinery), muscle spasms and tic-like movements of the head and face, restless legs syndrome, extrapyramidal effects.</li><li>Antimuscarinic effects — blurred vision, dry mouth, and urinary retention.</li><li>Skin — urticaria, rash, pruritus, photosensitivity.</li><li>Gastrointestinal — anorexia, gastric irritation, jaundice (rare).</li><li>Cardiovascular — palpitations, hypotension, arrhythmias.</li><li>Irritability and excitement in the neonate — avoid the use of promethazine in the two weeks prior to delivery.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI, 2020</a>]</p><!-- end field b8b47938-9096-4cea-ba7d-a77400a9da1e --><!-- end item db4ee633-6ae3-4d89-9fbe-a77400a9d771 -->","subChapters":[]},{"id":"37ee1c66-ac15-5869-a0fe-e81a41ba33ed","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 1b61e61d-4301-40bd-887c-a77400a9c5c3 --><h3>What are the contraindications and cautions when prescribing promethazine?</h3><!-- end field 1b61e61d-4301-40bd-887c-a77400a9c5c3 -->","summary":"","htmlStringContent":"<!-- begin item 1cfa6f19-9d25-42d8-9c19-a77400a9c3a4 --><!-- begin field 84fcf24b-30d8-4959-92bd-a77400a9c5c3 --><ul><li><strong>Promethazine should not be used in people:</strong><ul><li>With central nervous system (CNS) depression of any cause.</li></ul></li><li><strong>Promethazine should be used with caution in people with:</strong><ul><li>Hepatic impairment — avoid sedating antihistamines in severe liver disease.</li><li>Severe coronary artery disease.</li><li>Urinary retention.</li><li>Angle-closure glaucoma.</li><li>Pyloroduodenal obstruction.</li><li>Epilepsy.</li><li>Asthma, bronchitis, or bronchiectasis — promethazine may thicken or dry lung secretions and impair expectoration.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>]</p><!-- end field 84fcf24b-30d8-4959-92bd-a77400a9c5c3 --><!-- end item 1cfa6f19-9d25-42d8-9c19-a77400a9c3a4 -->","subChapters":[]},{"id":"1e9ab5a4-a4bc-5b87-9484-712ae9885f8f","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field b1ae7f79-6b52-4fbe-b852-a77400a9f963 --><h3>What drug interactions occur with promethazine?</h3><!-- end field b1ae7f79-6b52-4fbe-b852-a77400a9f963 -->","summary":"","htmlStringContent":"<!-- begin item 1940f4f8-d114-47b2-a74b-a77400a9f70a --><!-- begin field b0607b1e-1db7-40de-8222-a77400a9f963 --><ul><li>Avoid promethazine for 2 weeks after stopping a monoamine oxidase inhibitor (MAOI) — the combination of promethazine and an MAOI has rarely been reported to cause neuroleptic malignant syndrome or extrapyramidal symptoms.</li><li>Other combinations requiring caution include:<ul><li>Opioid analgesics — sedative effects may be enhanced when promethazine is given with opioid analgesics.</li><li>Alcohol — sedative effect may be increased by the combination of promethazine and alcohol.</li><li>Antimuscarinic drugs, tricyclic antidepressants, sedatives, and hypnotics — concomitant use with promethazine enhances the antimuscarinic and/or sedative action of these drugs.</li></ul></li><li>Promethazine has the potential to interact with immunological pregnancy tests (may give false-positive or false-negative results). It may also give a false negative result with skin tests by inhibiting the cutaneous histamine response — discontinue 72 hours in advance.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>]</p><!-- end field b0607b1e-1db7-40de-8222-a77400a9f963 --><!-- end item 1940f4f8-d114-47b2-a74b-a77400a9f70a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}